Table 2.
Prevalence of Transmitted Drug Resistance Among 536 Antiretroviral-Naive MSM HIV Patients, Including 266 Acute and 270 Chronic HIV-1 Infected Patients in You'an Hospital, Beijing, China
Total (536) | AHI/EHI (266) | CHI (270) | |||||
---|---|---|---|---|---|---|---|
n | % [95% CI] | n | % [95% CI] | n | % [95% CI] | p-Value | |
Any class | 42 | 7.8 [5.7–10.5] | 22 | 8.3 [5.2–12.3] | 20 | 7.4 [4.6–11.2] | 0.710 |
NRTI | 5 | 0.9 [0.3–2.2] | 3 | 1.1 [0.2–3.3] | 2 | 0.7 [0.1–2.7] | 0.641 |
NNRTI | 9 | 1.7 [0.8–3.3] | 5 | 1.9 [0.6–4.4] | 4 | 1.5 [0.4–3.8] | 0.720 |
PI | 33 | 6.2 [4.3–8.6] | 16 | 6.0 [3.5–9.6] | 17 | 6.3 [3.7–10] | 0.892 |
Single class | 39 | 7.3 [5.2–9.9] | 21 | 7.9 [5.0–11.9] | 18 | 6.7 [4.0–10.4] | |
Two classes | 1 | 0.2 [0–1.1] | 0 | 0 | 1 | 0.4 [0–2.2] | |
Three classes | 2 | 0.4 [0–1.5] | 1 | 0.4 [0–2.6] | 1 | 0.4 [0–2.2] |
MSM, men who have sex with men; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitors; single-, two-, or three-class resistance is defined as one or more TDR within one, two, or three antiretroviral drug classes, respectively.